Mylan Delays its Merger with Upjohn Due to COVID-19 Pandemic

 Mylan Delays its Merger with Upjohn Due to COVID-19 Pandemic

Mylan Delays its Merger with Upjohn Due to COVID-19 Pandemic

Shots:

  • Pfizer and Mylan delayed the closing of the Viatris merger (a merger b/w Upjohn and Mylan) due to the unprecedented circumstances amid COVID-19 pandemic, including associated delays in the regulatory review process
  • The companies anticipated the merger to be closed in H2’20 with no expected changes in the deal terms and Mylan’s EGM moved to Jun 30, 2020
  • The focus of both the companies remains the health and safety of their employees who are working towards the completion of the transaction while also maintaining their responsibility to meet patient needs during the pandemic

Click here ­to­ read full press release/ article | Ref: Business wire | Image: Market Scope

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post